BJUI Mini Reviews - Management of Renal Cancer in the Tyrosine Kinase Inhibitor Era: A View from 3 Years On
This review looks at four new drugs that have received recent regulatory approval: sorafenib, sunitinib, temsirolimus and bevacizumab.
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2008 UroToday ® All Rights Reserved |
